Mod GRF 1-29 (Modified GRF, CJC-1295 no DAC) is a modified analog of the first 29 amino acids of growth hormone-releasing hormone with enhanced stability. This tetrasubstituted peptide resists enzymatic degradation.

Mechanism of Action

Mod GRF 1-29 features four amino acid substitutions (positions 2, 8, 15, and 27) that protect against DPP-IV cleavage while maintaining GHRH receptor binding. These modifications extend half-life while preserving pituitary GH-releasing activity (Jette et al., 2005). GHRH-(1-29) administered twice daily reverses the decreased GH and IGF-I levels in elderly men (Corpas et al., 1992).

Research Applications

• Stabilized GHRH analog research (Jette et al., 2005)
• Pulsatile GH release studies (Corpas et al., 1992)
• Combined GHRH/GHRP synergy
• GH axis modulation
• Peptide stability research

Product Specifications

• Purity: ≥99% (HPLC verified)
• Molecular Weight: 3367.9 Da
• Form: Lyophilized powder
• Storage: -20°C

References

1. Jette L, et al. “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.” Endocrinology. 2005. PMID: 15817669
2. Corpas E, et al. “Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.” J Clin Endocrinol Metab. 1992. PMID: 1379256